Non-steroidal anti-inflammatory drugs

Last updated: November 01, 2022

Non-steroidal anti-inflammatory drugs

2.1.1

2.1.1

Septic arthritis
Borrelia burgdorferi (Lyme disease)
Treponema pallidum (Syphilis)
Sexually transmitted infections: Clinical
Borrelia species (Relapsing fever)
Back pain: Pathology review
Rheumatoid arthritis and osteoarthritis: Pathology review
Seronegative and septic arthritis: Pathology review
Gout and pseudogout: Pathology review
Systemic lupus erythematosus (SLE): Pathology review
Scleroderma: Pathology review
Sjogren syndrome: Pathology review
Bone disorders: Pathology review
Bone tumors: Pathology review
Myalgias and myositis: Pathology review
Neuromuscular junction disorders: Pathology review
Muscular dystrophies and mitochondrial myopathies: Pathology review
Vasculitis: Pathology review
Polymyalgia rheumatica
Vasculitis: Clinical
Reactive arthritis
Rheumatoid arthritis
Psoriatic arthritis
Rheumatoid arthritis: Clinical
Seronegative arthritis: Clinical
Pharmacokinetics: Drug absorption and distribution
Skin histology
Vasculitis
Pharmacokinetics: Drug metabolism
Pharmacokinetics: Drug elimination and clearance
Drug administration and dosing regimens
Fibrous, cartilage, and synovial joints
Ankylosing spondylitis
Non-steroidal anti-inflammatory drugs
Gout
Contracting the immune response and peripheral tolerance
Systemic lupus erythematosus
Systemic lupus erythematosus (SLE): Clinical
Antiphospholipid syndrome
Scleroderma
Phosphate, calcium and magnesium homeostasis
Glomerular filtration
Parathyroid hormone
Sodium homeostasis
Renin-angiotensin-aldosterone system
Kidney histology
Chronic kidney disease: Clinical
Renal azotemia
Prerenal azotemia
Acute kidney injury: Clinical
Postrenal azotemia
Renal failure: Pathology review
Rapidly progressive glomerulonephritis
Renal tubular acidosis
Renal clearance
Poststreptococcal glomerulonephritis
Membranoproliferative glomerulonephritis
Focal segmental glomerulosclerosis (NORD)
Electrolyte disturbances: Pathology review
Nephrotic syndromes: Pathology review
Nephritic syndromes: Pathology review

Transcript

Watch video only

Non-steroidal anti-inflammatory drugs or NSAIDs are mainly used to treat inflammation, pain, and fever. These conditions are related to an increased production of pro-inflammatory chemicals called prostaglandins.

NSAIDs work by decreasing the production of prostaglandins, thereby reducing inflammation, relieving pain, and reducing fever.

In order to understand how NSAIDs work, first we need to talk briefly about inflammation, which is the body’s response to a harmful stimulus, such as infection or injury.

So, during inflammation, your immune cells use an enzyme called phospholipase A2 to take membrane phospholipids and make a 20-carbon polyunsaturated fatty acid, called arachidonic acid.

Arachidonic acid is a substrate for an enzyme called cyclooxygenase or COX.

The enzyme cyclooxygenase exists in two different isoforms: COX-1 and COX-2.

COX-1 is a constitutive enzyme, meaning that it’s always active, while on the other hand, COX-2 is an inducible enzyme, meaning that it must be turned on to function. This is usually triggered by immune cells and vascular endothelial cells during inflammation.

Both enzymes produce prostaglandin E2 (PGE2) and prostacyclin (PGI2), which cause vasodilation and attract different immune cells to the area.

They also act on neurons that detect pain, called nociceptors, and make them more sensitive to stimuli by lowering their threshold for activation.

Finally, they stimulate the hypothalamus to increase the body temperature, causing fever.

Prostaglandin E2 also has other effects like causing uterine contractions, decreasing the secretion of acid, and increasing the production of protective mucus in the stomach.

So, in conditions such as inflammation, pain, or fever, NSAIDs can be used to inhibit cyclooxygenase and decrease the production of prostaglandins.

Depending on how they interact with these enzymes, NSAIDs are subdivided into 2 main groups: irreversible COX inhibitors, like aspirin; and reversible COX inhibitors, or non-aspirin NSAIDs.

Non-aspirin NSAIDs can be further subdivided into 2 groups: non-selective COX inhibitors, which include common medications like ibuprofen, and selective COX-2 inhibitors like celecoxib.

Alright, now let’s start with aspirin, also known as acetylsalicylic acid, which works by irreversibly inhibiting both COX-1 and COX-2.

Aspirin is taken perorally and most of the absorption occurs in the ileum.

Once absorbed into the bloodstream, aspirin irreversibly inhibits COX-1 in platelets by covalent acetylation, thereby decreasing production of thromboxane A2 in platelets.

Since thromboxane A2 is a platelet activator, this makes aspirin useful as an antiplatelet medication.

Since aspirin irreversibly prevents the platelets from synthesizing new COX-1 enzymes, aspirin’s effect will persist until there are enough new platelets produced that are able to produce COX-1 enzymes. This leads to increased bleeding time without affecting PT or PTT.

Next, in the liver, aspirin is metabolized into salicylate, which doesn’t have the antiplatelet effect, but it does have anti-inflammatory properties.

Salicylate works by inhibiting COX-2, thereby reducing prostaglandin production, leading to decreased inflammation, pain, and fever; so, it’s commonly used to treat headaches and musculoskeletal pain.

It’s also used for the short term treatment of chronic pain like osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.

It’s important to note that the effects of aspirin are dose-dependent: low doses under 300 mg/day work as an antiplatelet medication; medium doses between 300 and 2400 mg/day work as an antipyretic and analgesic; and high doses over 2400 mg/day work as an anti-inflammatory medication.

Low doses or “baby aspirin” in the form of 81 mg tablets are used long-term to help prevent heart attacks, strokes, and blood clot formation in people at high risk of developing blood clots.

Okay, moving on to non-selective COX inhibitors, which reversibly inhibit both COX-1 and COX-2. Common medications in this class include ibuprofen, naproxen, ketorolac, indomethacin, sulindac, meloxicam, and many others.

All these medications can be taken perorally, but ketorolac, ibuprofen, and indomethacin are the only NSAIDs that are also available in parenteral form.

Just like aspirin, these medications also inhibit COX-1 and have an antiplatelet effect, but because they’re reversible inhibitors, their effect is transient so they won’t provide the same benefit as aspirin.

If taken together with aspirin, they will even compete for the binding sites on COX-1, which results in a decrease in the antiplatelet effect of aspirin.

Next, these medications also inhibit COX-2, which reduces inflammation, pain, and fever, so they have the same indications as aspirin.

However, ibuprofen, naproxen, and indomethacin are also used to reduce inflammation during an acute gout attack, where aspirin should be avoided since it competes with uric acid for excretion in the kidneys, which might worsen the symptoms of gout.

Indomethacin is also used to close patent ductus arteriosus in neonates and premature infants, while ketorolac is used to treat severe acute pain, usually after surgery.

Now moving on to selective COX-2 inhibitors, the main medication in this group is celecoxib.

Celecoxib reversibly inhibits COX-2, so it can treat pain and inflammation like the other NSAIDs.

Since it doesn’t affect COX-1, it lacks the antiplatelet effect seen in aspirin. On the other hand, it doesn’t compete with aspirin for COX-1 like the reversible nonselective COX inhibitors, so it can be combined with aspirin without decreasing its antiplatelet effect.

For side effects, both aspirin and the nonselective COX inhibitors can cause problems by blocking COX-1 in many parts of the body.

Inhibition of COX-1 in the stomach decreases the concentration of cytoprotective prostaglandins, which can lead to gastritis, gastric ulcers, or even bleeding.

Reversible inhibitors of COX-1 cause less gastrointestinal problems when compared to aspirin, and selective COX-2 inhibitors like celecoxib causes the least GI side effects since they don’t affect COX-1.

In the kidneys, all NSAIDs inhibit COX-2 which decreases the level of prostaglandins that dilate the renal artery, causing a reduction in renal blood flow. This reduced blood flow tricks the kidney into thinking the blood pressure is low, so in order to increase it, they activate the renin-angiotensin-aldosterone system, which can lead to hypertension.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
  4. "Aspirin and NSAIDs; benefits and harms for the gut" Best Pract Res Clin Gastroenterol (2012)
  5. "Gastrointestinal safety of selective COX-2 inhibitors" Curr Pharm Des (2002)
  6. "Clinical pharmacology of selective COX-2 inhibitors" Int J Immunopathol Pharmacol (2003)
  7. "The Role of Human Carboxylesterases in Drug Metabolism: Have We Overlooked Their Importance?" Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy (2013)